Phase 2a Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Repeated Administrations Over 4 Weeks of the Hepcidin Antagonist PRS-080#022-DP in Anemic Chronic Kidney Disease Patients Undergoing Hemodialysis
Phase of Trial: Phase II
Latest Information Update: 09 Mar 2018
At a glance
- Drugs PRS 080 (Primary)
- Indications Iron deficiency anaemia
- Focus Adverse reactions
- Sponsors Pieris Pharmaceuticals
- 09 Mar 2018 According to a Pharmaceuticals media release, results from the study are expected in the second half of 2018.
- 27 Oct 2017 Status changed from planning to recruiting.
- 09 Aug 2017 According to a Pharmaceuticals media release, the company is planning filing of separate clinical trial applications with the German and Czech Republic regulatory authorities to conduct this trial during this quarter.